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1. Introduction
Inhibition of glycogen phosphorylase (GP) can be a new
therapeutic method for the treatment of type 2 diabetes mellitu
and potential application of GP inhibitors (GPIs) in some othe
diseased states, such as early cardiac and cardiovascular disorder
in non-diabetics, cardiac arrhythmias, ischemic injuries, and tumo
growth was also proposed.1–5 A large array of compounds wa
shown to have inhibitory effect against GP under in vitro cond
tions.4,6 Among these molecules glucose derivatives are the mos
intensively investigated GPIs, and detailed studies can be foun
in the literature on their structure–activity relationships (SAR).5
Some glucose derived GPIs had in vivo hypoglycaemic8 and othe
interesting physiological effects.9
Widely studied glucose analogue GPIs are derivatives o
b-D-glucopyranosylamine, such as N-acyl-b-D-glucopyranosylam
10–13 11,14ines (I in Chart 1, e.g., Ki = 10–13 lM against rabbit muscle
GPb (RMGPb)15 for R = 2-naphthyl), N-aryl-N0-b-D-glucopyranosyl
ureas4 (II, e.g., Ki = 5.2 lM (RMGPb) for R = 2-naphthyl), as well
as N-acyl-N0-b-D-glucopyranosyl urea derivatives4,16 (III, e.g.,
Ki = 0.35 lM (RMGPb) for R = 2-naphthyl) which inhibited the en-
zyme in or below the low micromolar range. Micromolar efﬁciency
was reported also for 4-(b-D-glucopyranosyl)thiosemicarbazones
of aromatic aldehydes17,18 (IV X = S, e.g., IC50 = 5.7 lM (RMGPb)
0008-6215/$ - see front matter  2013 Published by Elsevier Ltd.
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4,6-tetra-O-acetyl-b-D-glucopyranosyl)semicarbazones were synthesized b
ydrazones onto O-peracetylated b-D-glucopyranosyl isocyanate. Oxidativ
precursors gave O-protected 2-(b-D-glucopyranosylamino)-5-substituted
l of the O-acetyl protecting groups under Zemplén conditions gave te
icromolar inhibition against rabbit muscle glycogen phosphorylase b. Be
s were 4-(b-D-glucopyranosyl)semicarbazones of 4-ﬂuorobenzaldehyd
hyde (Ki = 5.5 lM) and 2-(b-D-glucopyranosylamino)-5-(4-methylphenyl
).
 2013 Published by Elsevier Lt
for Ar = 4-ﬂuorophenyl). Compounds V, in which the sugar an
the aromatic parts are interchanged in comparison to IV, have ver
recently been shown to be GPIs (Ki = 29 lM for V X = O, an
Ki = 300 lM for V X = S against RMGPb).19
Replacement of the NHCO moiety by 1,2,3-triazole (a non
classical bioisosteric heterocyclic linker A) in molecules I resulte
in effective GP inhibitors20 (IA, e.g., Ki = 16 lM (RMGPb) fo
R = 2-naphthyl). Enzymatic tests and crystallographic studies hav
shown high similarity of the amide (I) and the 1,2,3-triazole (IA
type molecules both in binding strength and structural feature
of the enzyme–inhibitor complexes.14 Replacement of the NHC
moiety with isomeric oxadiazoles B, C, and D resulted in inhibitor
IB–D with varying efﬁciency. Among these molecules the 3-aryl-5
b-D-glucopyranosyl-1,2,4-oxadiazoles IC proved to be the mos
effective compounds (e.g., Ki = 2.4 lM(RMGPb) for R = 2-naph
thyl).21,22 Bioisosteric replacement studies were also carried ou
with compounds III.
As part of a program to systematically replace NHCOmoieties of
80GPIs I–III by heterocyclic bioisosteres, herein we report on the
syntheses and enzymatic tests of a series of 2-(b-D-glucopyrano-
sylamino)-5-substituted-1,3,4-oxadiazoles IIB.
For the construction of 1,3,4-oxadiazole rings from acyclic pre-
cursors acidic treatment of N,N0-diacyl- (or N-acyl-N0-thioacyl)-
hydrazines as well as oxidative cyclization of acylhydrazones are
the most frequently used procedures, and both methods were
applied for the syntheses of 2-amino-5-substituted-1,3,4-oxadiaz-
oles, too.24 2-Glycosylamino-5-substituted-1,3,4-oxadiazoles are
also known and have been synthesized from glycosyl isothiocya-
90nates either by the addition of acid hydrazides followed by ring
13), http://dx.doi.org/10.1016/j.carres.2013.04.025
closure of the resulting 1-acyl-4-glycosyl-thiosemicarbazides25–27
or by chlorination to give intermediate glycosyl isocyanide dichlo-
rides to be cyclized with acid hydrazides.28
In this work we investigated the synthesis of compounds IIB
from aldehyde 4-glycosyl-semicarbazones (cf. O-protected IV
X = O in Chart 1), a route which, to the best of our knowledge,
has not yet been applied to obtain 2-glycosylamino-1,3,4-oxadiaz-
oles. On the other hand, the preparation of semicarbazones IV
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Pl= O) gave the opportunity to compare their GPI properties to
e corresponding thiosemicarbazones IV (X = S).
Results and discussion
. Syntheses
For the formation of the target oxadiazoles oxidative ring
sure of aromatic aldehyde 4-(2,3,4,6-tetra-O-acetyl-b-D-gluco-
ranosyl)semicarbazones (similar to that applied for the
ntheses of 2-aryl-5-(2,3,4,6-tetra-O-benzoyl-b-D-glucopyrano-
l)-1,3,4-oxadiazoles22) was envisaged as the key step. To this
d, O-peracetylated 4-(b-D-glucopyranosyl)semicarbazide 2 was
epared (Scheme 1) by the reaction of glucopyranosyl isocyanate
9 (obtained from the corresponding glucopyranosylamine30)
th hydrazine reagents under different reaction conditions
agents: NH2NH2HCl, NH2NH2HOAc; solvents: dry pyridine,
y CH2Cl2, and 1 equiv Et3N). The best yield (75%) was achieved
th NH2NH2HOAc in dry CH2Cl2 in the presence of Et3N. In each
the above reactions bis-glucopyranosyl urea was also isolated in
rious amounts which could be due to the presence of traces of
ter in the mixtures.31
In order to get semicarbazones 3–9 condensation of semicarb-
ide 2 with the proper aldehydes was planned. However,
actions of 2 with 2-napthaldehyde in dry EtOH or dry toluene
the presence of catalytic amounts of either AcOH or CF3COOH
O
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a
eme 1. Reagents and conditions: (a) NH2NH2HOAc, dry CH2Cl2, Et3N, rt; (b) ArCH@ease cite this article in press as: Tóth, M.; et al. Carbohydr. Res. (2013),reﬂux temperature resulted in complex reaction mixtures.
erefore, b-D-glucopyranosyl isocyanate 2 was reacted with alde-
de hydrazones32 in boiling dry dioxane to result in the target
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Phthe Zemplén protocol to give excellent yields of semicarbazones
–16.
Ring closing reactions of the precursors under oxidative condi-
ns were studied next. Semicarbazones 3, 5–7, and 9 were
acted with phenyliodonium diacetate (PIDA) in CH2Cl2 at rt
cheme 2) to furnish the corresponding O-peracetylated 2-(b-D-
copyranosylamino)-5-substituted-1,3,4-oxadiazoles 17, 19–21,
d 23, respectively, in moderate yields. Application of Pb(OAc)4
the oxidizing agent in glacial AcOH at 80 C resulted in better
lds for 1,3,4-oxadiazoles 17–22 (compare yields under condi-
ns a and b in Scheme 2). Debenzoylations were performed by
e Zemplén protocol to give mostly good yields of 1,3,4-oxadiaz-
s 24–30 (Scheme 2).
Structural elucidation of the new compoundswas based on NMR
ectra. The b-D-anomeric conﬁguration was indicated by the 8.1–1 conformation of each compound. Coupling of 1-H and N(4)H
.2–9.8 Hz) could be observed in the spectra of semicarbazones
9 only. For the oxadiazoles 17–23 1-H and NH appeared as
ublets and singlets, respectively, probably because of a speciﬁc
hedral angle between these protons resulting in a very small
upling constant. A 1H spectrum of semicarbazone 5 recorded
mediately (5 min) after dissolution showed the presence of
e compound only. A NOE difference spectrum obtained by irradi-
ion of the N(2)H signal gave positive NOE for the signal of CH@N
.86 ppm) and N(4)H (7.25 ppm) indicating E conﬁguration of the
N double bond. After 72 h the 1H spectrum of 5 exhibited two
ts of signals as a result of E/Z isomerisation (1:1 ratio, character-
ic chemical shifts (d, ppm) for the E isomer: 10.10 (N(2)H), 7.86
H@N), 7.25 (N(4)H); for the Z isomer: 8.62 (N(2)H), 7.41 (CH@N),
Ar
O
OH
HO
HO
OH
H
N
O
H
N N Ar
c
10 (99%)
11 (98%)
12 (93%)
13 (98%)
14 (94%)
15 (80%)
16 (98%)
61-01
H2, dry dioxane, reﬂux; (c) NaOMe, dry MeOH, rt.http://dx.doi.org/10.1016/j.carres.2013.04.025
7.15 (N(4)H). These upﬁeld shifts for the Z isomer are in accord with
literature experiences for semicarbazones,33 however, contrast
those for O-peracetylated 4-(b-D-glucopyranosyl)thiosemicarba-
zones where the N(2)H signals were reported to appear at 10.1
160 (E) and 14.6 (Z) ppm.17
2.2. Enzyme inhibition studies
The kinetic parameters (inhibition potency against rabbit mus-
cle glycogen phosphorylase b (RMGPb)) of the deprotected com-
pounds were determined according to the protocol described
earlier.34 The results are summarized in Table 1 showing the inhib-
itory efﬁciency of some relevant reference compounds, as well.
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contribution of the second carbonyl unit to the binding. This is cor-
roborated by the smaller decrease caused by the change 37?39
than that of 37?10. A formal reversal of the thiosemicarbazone
linker as in 4019 makes a very large decrease in the binding
strength most probably because the thiocarbonyl in the position
200of the ‘second amide’ moiety is much less suitable to make strong
interactions to the enzyme.
Replacement of the NHCO moiety in compounds type II by the
1,3,4-oxadiazole ring (compounds type IIB: 24–30) resulted in
moderate GPIs. For the phenyl and 1-naphthyl substituted pairs
34–24 and 35–29 there is no signiﬁcant change in the binding
strength. Substitution in the 4-position of the aromatic ring (25–
27) resulted in a small and unspeciﬁc increase of the efﬁciency,
while the 3-chloro replacement (28) made a somewhat weaker
inhibitor. Based on these results one could argue that the 1,3,4-oxa-
210diazole is an acceptable bioisosteric replacement of the NHCOmoi-
ety in this system. However, this argument is weakened by the 5
times worse inhibition of 30 as compared to 36 for which a specu-
lative explanation can be that the large and rigid aglycon is unable
to ﬁnd an accomodatable position in the binding site of the enzyme.
3. Conclusion
Reaction of O-peracetylated b-D-glucopyranosyl isocyanate
with different hydrazones gave the corresponding aldehyde 4-(2,
3,4,6-tetra-O-acetyl-b-D-glucopyranosyl)semicarbazones in good
yields. Oxidation of these compounds by PIDA or more advanta-
220geously by Pb(OAc)4 resulted in 2-(b-D-glucopyranosylamino)-5-
substituted-1,3,4-oxadiazoles. Zemplén deacetylation furnished
test compounds which proved low micromolar inhibitors against
RMGPb. Structure–activity considerations allow to estimate the
relative contribution to the binding by carbonyl and thiocarbonyl
groups of N-acyl-N0-glucopyranosyl urea type GPIs, and raise the
possibility of applying 1,3,4-oxadiazoles as bioisosteric replace-
ments of NHCO moieties.
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Scheme 2. Reagents and conditions: (a) PIDA, CH2Cl2, rt; (b) Pb(OAc)4, AcOH, 80 C;
(c) NaOMe, dry MeOH, rt.
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2 May 2013Type IV semicarbazones 10–16, the ‘open chain’ precursors o
the target compounds of this work, proved low micromolar inhib
itors with the practically equipotent 4-nitrophenyl (12) an
2-naphthyl (16) compounds as the best ones. The strong bindin
of 16 ﬁts the general trend observed with several glucose deriva
tives exhibiting most efﬁcient inhibition with large hydrophob
groups in the aglycons.4 A comparison to the structurally relate
thiosemicarbazone counterparts would be possible for the pairs
12–31, 13–32, and 14–33, however, the reported inhibition data1
for the sulfur containing compounds 31–33 are IC50 values no
directly comparable with the inhibitor constants. Nevertheless,
is interesting to note that the tendency is different in the two ser
ies: within semicarbazones the 4-nitrophenyl (12) compoun
while within the thiosemicarbazones the 4-ﬂuorophenyl (32
derivative proved 4 to 6 times stronger inhibitors than the nex
best ones 14 and 33, respectively.
A comparison of inhibition of 10 to that of the biuret type com
pound 37,4 having the same number of atoms between the suga
and the aromatic ring, indicates the latter to be a twice bette
inhibitor than the former one. This may underline the importanc
of both carbonyl units in the binding. On the other hand, 10 bind
15-fold stronger than 384 with two C@O moieties but also havin
a rotatable CH2 unit in place of NH, thereby emphasizing that th
rigidity of 10 makes an important contribution to the binding.
A further comparison of 10 to type V compound 39,19 wherei
the semicarbazone linker is formally reversed between th
carbohydrate ring and the phenyl group, shows a moderat
strengthening of the inhibition that may refer to the highePlease cite this article in press as: Tóth, M.; et al. Carbohydr. Res. (204.1. General methods
Melting points were measured in open capillary tubes or on
Koﬂer hot-stage and are uncorrected. Optical rotations wer
determined with a Perkin–Elmer 241 polarimeter at room temper
ature. NMR spectra were recorded with Bruker 360 (360/90 MH
for 1H/13C) or Bruker 400 (400/100 MHz for 1H/13C) spectrometer
Chemical shifts are referenced to TMS as the internal referenc
(1H), or to the residual solvent signals (13C). Microanalyses wer
performed on an Elementar vario Micro cube. ESIMS were recorde
with a Bruker micrOTOF-Q instrument. TLC was performed on DC
Alurolle Kieselgel 60 F254 (Merck). TLC plates were visualized unde
UV light, and by gentle heating. For column chromatograph
Kieselgel 60 (Merck, particle size (0.063–0.200 mm) was applied
Organic solutions were dried over anhydrous MgSO4, and concen
trated under diminished pressure at 40–50 C (water bath). Alde
hyde hydrazones were obtained from the correspondin
aldehydes and H2NNH2H2O according to a literature procedure.3
4.2. General procedure I for the synthesis of aromatic aldehyd
4-(2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl)semicarbazones
(3–9)
2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl isocyanate29 (1
0.22 g, 0.59 mmol) was added to the solution of an aldehyde hydra
zone (0.27 g, 1.80 mmol) in dry dioxane (5 mL). The reaction mix
ture was stirred at reﬂux temperature for 24 h. When the reactio13), http://dx.doi.org/10.1016/j.carres.2013.04.025
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Pls complete (TLC 1:1 EtOAc/hexane) the reaction mixture was
tered with suction, and the solvent was evaporated under
duced pressure. The crude product was puriﬁed by column
romatography.
. General procedure II for the synthesis of 5-aryl-2-(2,3,4,6-
tra-O-acetyl-b-D-glucopyranosylamino)-1,3,4-oxadiazoles
7–23)
An aldehyde 4-(2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl)
micarbazone (3–9, 0.03 mmol/mL) was dissolved in CH2Cl2, then
A (1.1 equiv) was added, and themixturewas stirred at rt.When
e reaction was complete (TLC, 1:1 EtOAc/hexane) the solvent was
aporated under reduced pressure, and the residuewas puriﬁed by
lumn chromatography.
. General procedure III for the synthesis of 5-aryl-2-(2,3,4,6-
tra-O-acetyl-b-D-glucopyranosylamino)-1,3,4-oxadiazoles
7–23)
An aldehyde 4-(2,3,4,6-tetra-O-acetyl-b-D-glucopyrano-
l)semicarbazone (3–9, 0.03 mmol/mL) was dissolved in glacial
OH, then Pb(OAc)4 (1 equiv) was added, and the mixture was
rred at 80 C. The reaction was monitored by TLC (1:1 EtOAc/
xane). When the reaction was complete, the reaction mixture
s diluted with H2O (10 mL), and washed with EtOAc (3 
le 1
ibition of rabbit muscle glycogen phosphorylase b (RMGPb) by selected glucose deriv
Ar
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HO
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N
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X = O X = S
10 38 —
Me
11 136 —
O2N
12 4.5 31 25.71
F
13 48 32 5.718
Cl
14 30 33 23.21
15 124 —
16 5.5 —
O
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37 X = NH 214
38 X = CH2 6004mL). The organic layer was separated, dried, and the solvent (5
ease cite this article in press as: Tóth, M.; et al. Carbohydr. Res. (2013),s evaporated under reduced pressure. The residue was puriﬁed
column chromatography.
. General procedure IV for the removal of O-acetyl protecting
oups
An O-peracetylated compound (100 mg) was dissolved in dry
eOH (1 mL) and a solution of NaOMe (0.1 M in MeOH) was added
the solution in a catalytic amount. The reaction mixture was
rred at rt. When the reaction was complete (TLC, 3:1 CHCl3/
eOH) the solution was neutralized with a cation exchange resin
berlyst 15 (H+ form). The resin was ﬁltered off with suction
d the ﬁltrate was evaporated under reduced pressure. The crude
oduct was puriﬁed by column chromatography.
. 4-(2,3,4,6-Tetra-O-acetyl-b-D-glucopyranosyl)semicarbazide
)
NH2NH2HOAc (97%, 26.6 mg, 0.28 mmol) was added to the
lution of 2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl isocyanate29
, 0.10 g, 0.27 mmol) and Et3N (39 lL, 0.28 mmol) in dry CH2Cl2
mL). The reaction mixture was stirred at rt. When the reaction
s complete (TLC 5:1 EtOAc/hexane) the solvent was evaporated
der reduced pressure. The crude product was puriﬁed by column
s and the new compounds (Ki [lM])
O
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2 May 20136.53, 6.27 (4H, 4 s, NH), 5.32, 5.14, 5.07, 4.97 (4H, 4 pt, J = 8.9
9.6 Hz in each, H-1, H-2, H-3, H-4), 4.31–4.12 (2H, m, H-6a, H
6b), 3.85–3.83 (1H, m, H-5), 2.08, 2.07, 2.04 (12H, 3 s, CH3). 13
NMR (CDCl3, 360 MHz) d (ppm) 170.0, 169.4, 169.3, 169.2 (CO
157.2 (NHCONH), 78.5, 72.8, 71.7, 70.4, 67.9 (C-1 to C-5), 61.
(C-6), 20.5, 20.3 (CH3). Anal. Calcd for C15H23N3O10 (405.36): C
44.44; H, 5.72; N, 10.37. Found: C, 44.58; H, 5.84; N, 10.26.
4.7. Benzaldehyde 4-(2,3,4,6-tetra-O-acetyl-b-D-glucopyranosyl
semicarbazone (3)
From isocyanate 1 (0.10 g, 0.27 mmol) and benzaldehyd
hydrazone (0.064 g, 0.54 mmol) according to General procedure
(Section 4.2). Puriﬁed by column chromatography (1:1 EtOAc
hexane) to yield 110 mg (83%) of 3 as a white amorphous produc
[a]D –61 (c 0.99, CHCl3); Rf: 0.58 (5:1 EtOAc/hexane); 1H NM
(CDCl3, 360 MHz) d (ppm) 9.47 (1H, br s, NH), 7.77 (1H, s, CH@N
7.70–7.66 (2H, m, Ar), 7.43–7.40 (3H, m, Ar), 7.16 (1H, d
J1,NH = 9.5 Hz, NH), 5.39, 5.28, 5.15, 5.13 (4H, 4 pt, J = 9.5, 9.7 H
in each, H-1, H-2, H-3, H-4), 4.38 (1H, dd, J6a,6b = 12.5 Hz, H-6a
4.12 (1H, dd, H-6b), 3.92 (1H, ddd, J5,6a = 4.1 Hz, J5,6b = 1.8 H
J4,5 = 10.1 Hz, H-5), 2.08, 2.05, 2.04, 2.03 (12H, 4 s, CH3). 13C NM
(CDCl3, 360 MHz) d (ppm) 170.7, 170.5, 170.0, 169.5 (CO), 155.
(NHCONH), 142.6 (CH@N), 133.6, 130.0, 128.7, 127.1 (Ar), 79.3
73.2, 72.8, 70.3, 68.2 (C-1 to C-5), 61.6 (C-6), 20.7, 20.6 (CH3). Ana
Calcd for C22H27N3O10 (493.46): C, 53.55; H, 5.51; N, 8.52. Found: C
53.46; H, 5.61; N, 8.60.
4.8. 4-Methylbenzaldehyde 4-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosyl)semicarbazone (4)
From isocyanate 1 (0.40 g, 1.07 mmol) and 4-methylbenzalde
hyde hydrazone (0.29 g, 2.14 mmol) according to General proce
dure I (Section 4.2). Puriﬁed by column chromatography (1:
EtOAc/hexane) to yield 390 mg (72%) of 4 as a white amorphou
product. [a]D –50 (c 0.86, CHCl3); Rf: 0.66 (5:1 EtOAc/hexane); 1
NMR (CDCl3, 360 MHz) d (ppm) 9.21 (1H, br s, NH), 7.71 (1H,
CH@N), 7.56 (2H, d, J = 8.0 Hz, Ar), 7.27–7.20 (2H, m, Ar), 7.1
(1H, d, J1,NH = 9.5 Hz, NH), 5.37, 5.26, 5.14, 5.12 (4H, 4 p
J = 9.5 Hz in each, H-1, H-2, H-3, H-4), 4.36 (1H, dd, J6a,6b = 12.5 H
H-6a), 4.11 (1H, dd, H-6b), 3.89 (1H, ddd, J5,6a = 4.1 H
J5,6b = 1.9 Hz, J4,5 = 10.1 Hz, H-5), 2.39, 2.08, 2.05, 2.04, 2.02 (16H
5 s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 170.7, 170.5, 170.
169.5 (CO), 155.7 (NHCONH), 142.6 (CH@N), 140.3, 130.8, 129.5
127.0 (Ar), 79.4, 73.2, 72.9, 70.3, 68.2 (C-1 to C-5), 61.7 (C-6
21.5, 20.7 (CH3). Anal. Calcd for C23H29N3O10 (507.49): C, 54.43
H, 5.76; N, 8.28. Found: C, 54.32; H, 5.64; N, 8.38.
4.9. 4-Nitrobenzaldehyde 4-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosyl)semicarbazone (5)
From isocyanate 1 (0.40 g, 1.07 mmol) and 4-nitrobenzaldehyd
hydrazone (0.37 g, 2.14 mmol) according to General procedure
(Section 4.2). Puriﬁed by column chromatography (1:1 EtOAc/hex
ane) to yield 380 mg (66%) of 5 as an orange amorphous produc
[a]D 71 (c 0.35, CHCl3); Rf: 0.18 (1:1 EtOAc/hexane); 1H NM
(CDCl3, 400 MHz) d (ppm) 10.10 (1H, br s, NH), 8.29 (2H, d
J = 8.8 Hz, Ar), 7.87 (2H, d, J = 8.8 Hz, Ar), 7.86 (1H, s, CH@N), 7.2
(1H, d, J1,NH = 9.2 Hz, NH), 5.41, 5.24, 5.14, 5.12 (4H, 4 pt, J = 9.3
9.8 Hz in each, H-1, H-2, H-3, H-4), 4.38 (1H, dd, J6a,6b = 12.5 H
H-6a), 4.13 (1H, dd, H-6b), 3.91 (1H, J5,6a = 4.1 Hz, J5,6b = 2.1 H
J4,5 = 9.9 Hz, m, H-5), 2.09, 2.06, 2.04 (12H, 3 s, CH3). 13C NM
(CDCl3, 360 MHz) d (ppm) 170.7, 170.5, 169.9, 169.4 (CO), 155.
(NHCONH), 148.2 (C–NO2), 139.8 (CH@N), 139.6, 127.5, 124.
(Ar), 79.3, 73.2, 72.5, 70.4, 68.1 (C-1 to C-5), 61.6 (C-6), 20.Please cite this article in press as: Tóth, M.; et al. Carbohydr. Res. (20(CH3). Anal. Calcd for C22H26N4O12 (538.46): C, 49.07; H, 4.87; N
10.40. Found: C, 48.98; H, 4.80; N, 10.52.
4.10. 4-Fluorobenzaldehyde 4-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosyl)semicarbazone (6)
From isocyanate 1 (0.25 g, 0.67 mmol) and 4-ﬂuorobenzalde
hyde hydrazone (0.19 g, 1.23 mmol) according to General proce
dure I (Section 4.2). Puriﬁed by column chromatography (1:
EtOAc/hexane) to yield 260 mg (76%) of 6 as a white amorphou
product. [a]D –54 (c 0.27, CHCl3); Rf: 0.22 (1:1 EtOAc/hexane); 1
NMR (CDCl3, 360 MHz) d (ppm) 10.09 (1H, br s, NH) 7.78 (1H,
CH@N), 7.68 (2H, dd, J = 5.6 Hz, J = 7.9 Hz, Ar), 7.21–7.07 (3H, m
Ar, NH), 5.41, 5.29, 5.15, 5.12 (4H, 4 pt, J = 9.3, 9.9 Hz in each, H
1, H-2, H-3, H-4), 4.38 (1H, dd, J5,6a = 3.7 Hz, J6a,6b = 12.5 Hz, H
6a), 4.12 (1H, dd, J5,6b < 1 Hz, H-6b), 3.97–3.89 (1H, m, H-5), 2.0
(12H, s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 170.6, 170.5
169.9, 169.4 (CO), 163.7 (d, J = 250.0 Hz, Ar), 155.8 (NHCONH
141.4 (CH@N), 129.9 (Ar), 128.9 (d, J = 7.3 Hz, Ar), 115.8 (d
J = 22.0 Hz, Ar), 79.3, 73.1, 72.7, 70.3, 68.1 (C-1 to C-5), 61.6 (C
6), 20.5 (CH3). Anal. Calcd for C22H26FN3O10 (511.45): C, 51.66; H
5.12; N, 8.22. Found: C, 51.54; H, 5.23; N, 8.33.
4.11. 3-Chlorobenzaldehyde 4-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosyl)semicarbazone (7)
From isocyanate 1 (0.22 g, 0.59 mmol) and 3-chlorobenzalde
hyde hydrazone (0.18 g, 1.18 mmol) according to General proce
dure I (Section 4.2). Puriﬁed by column chromatography (1:
EtOAc/hexane) to yield 222 mg (71%) of 7 as a white amorphou
product. [a]D –65 (c 1.06, CHCl3); Rf: 0.61 (5:1 EtOAc/hexane); 1
NMR (CDCl3, 360 MHz) d (ppm) 9.60 (1H, br s, NH), 7.64–7.4
(3H, m, Ar, CH@N), 7.31–7.27 (2H, m, Ar), 7.12 (1H, d, J1,NH = 9.2 H
NH), 5.31, 5.16, 5.07, 5.05 (4H, 4 pt, J = 9.2, 9.7 Hz in each, H-1, H-2
H-3, H-4), 4.29 (1H, dd, J5,6a = 3.9 Hz, J6a,6b = 12.4 Hz, H-6a), 4.0
(1H, dd, J5,6b = 1.0 Hz, H-6b), 3.87–3.80 (1H, m, H-5), 2.02, 1.9
(12H, 2 s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 170.7, 170.5
170.0, 169.5 (CO), 155.7 (NHCONH), 141.0 (CH@N), 135.4, 134.9
130.0, 126.9, 125.3 (Ar), 79.5, 73.3, 72.7, 70.4, 68.3 (C-1 to C-5
61.7 (C-6), 20.7, 20.6 (CH3). Anal. Calcd for C22H26ClN3O1
(527.91): C, 50.05; H, 4.96; N, 7.96. Found: C, 50.16; H, 4.84; N
7.85.
4.12. 4-(1-Naphthaldehyde) 4-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosyl)semicarbazone (8)
From isocyanate 1 (0.40 g, 1.07 mmol) and 1-naphtaldehyd
hydrazone (0.37 g, 2.14 mmol) according to General procedure
(Section 4.2). Puriﬁed by column chromatography (1:1 EtOAc/hex
ane) to yield 520 mg (89%) of 8 as a yellow amorphous product. [a]
53 (c 0.96, CHCl3); Rf: 0.63 (5:1 EtOAc/hexane); 1H NMR (CDCl
360 MHz) d (ppm) 9.63 (1H, br s, NH), 8.52 (1H, d, J = 8.5 Hz, Ar
8.44 (1H, s, CH@N), 7.93–7.90 (3H, m, Ar), 7.68 (1H, pt, J = 8.1
8.3 Hz, Ar), 7.58–7.51 (2H, m, Ar), 7.17 (1H, d, J1,NH = 9.6 Hz, NH
5.42, 5.34, 5.17, 5.16 (4H, 4 pt, J = 9.5, 9.7 Hz in each, H-1, H-2, H
3, H-4), 4.37 (1H, dd, J6a,6b = 12.5 Hz, H-6a), 4.11 (1H, dd, H-6b
3.94 (1H, ddd, J5,6a = 3.9 Hz, J5,6b = 2.0 Hz, J4,5 = 10.2 Hz, H-5), 2.07
2.06, 2.05 (12H, 3 s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm
170.7, 170.6, 170.0, 169.5 (CO), 155.7 (NHCONH), 142.1 (CH@N
133.8, 130.5, 130.7, 128.9, 128.8, 127.3, 126.2, 125.3, 123.7 (Ar
79.4, 73.3, 72.9, 70.3, 68.2 (C-1 to C-5), 61.6 (C-6), 20.7, 20.
(CH3). Anal. Calcd for C26H29N3O10 (543.52): C, 57.45; H, 5.38; N
7.73. Found: C, 57.56; H, 5.27; N, 7.85.13), http://dx.doi.org/10.1016/j.carres.2013.04.025
4.1
py
hy
(S
420 an
7
36
7.5
5.1
(1
J5,
13C
(C
12
430 (C
(5
4.1
(S
M
[a
(D
Ar
J6a
440 (4
36
12
6)
12
4.1
glu
(S
M
450 [a
(C
J =
H-
dd
2.3
(N
79
fo
52
460 4.1
se
(S
M
uc
(C
d,
1)
J5,
470 or
NM
NO
71
(3
15
4.1
se
(S
480M
[a
(C
J =
J1,
6b
H-
J =
J =
(C
49048
4.1
6 M. Tóth et al. / Carbohydrate Research xxx (2013) xxx–xxx
CAR 6468 No. of Pages 10, Model 5G
2 May 2013
Pl3. 4-(2-Naphthaldehyde) 4-(2,3,4,6-tetra-O-acetyl-b-D-gluco-
ranosyl)semicarbazone (9)
From isocyanate 1 (0.27 g, 0.71 mmol) and 2-naphtaldehyde
drazone (0.24 g, 1.42 mmol) according to General procedure I
ection 4.2). Puriﬁed by column chromatography (1:1 EtOAc/hex-
e) to yield 310 mg (80%) of 9 as a yellow amorphous product. [a]D
3 (c 0.93, CHCl3); Rf: 0.64 (5:1 EtOAc/hexane); 1H NMR (CDCl3,
0 MHz) d (ppm) 9.83 (1H, s, NH), 7.99–7.83 (6H, m, Ar, CH@N),
3–7.50 (2H, m, Ar), 7.26 (1H, d, J1,NH = 9.8 Hz, NH), 5.42, 5.32,
7, (4H, 3 pt, J = 9.3, 9.6 Hz in each, H-1, H-2, H-3, H-4), 4.39
H, dd, J5,6a = 3.8 Hz, J6a,6b = 12.5 Hz, H-6a), 4.14 (1H, dd,
6b < 1.0 Hz, H-6b), 3.97–3.94 (1H, m, H-5), 2.06 (12H, s, CH3).
NMR (CDCl3, 360 MHz) d (ppm) 170.7, 170.6, 170.0, 169.5
O), 155.7 (NHCONH), 142.1 (CH@N), 134.2, 133.1, 131.4, 128.7,
8.3, 127.9, 127.0, 126.6, 122.7 (Ar), 79.5, 73.3, 72.9, 70.4, 68.3
-1 to C-5), 61.7 (C-6), 20.6 (CH3). Anal. Calcd for C26H29N3O10
43.52): C, 57.45; H, 5.38; N, 7.73. Found: C, 57.57; H, 5.49; N, 7.63.
4. Benzaldehyde 4-(b-D-glucopyranosyl)semicarbazone (10)From 3 (0.15 g, 0.30 mmol) according to General procedure IV se
(S
M
[a
(C
(1
H-
5005)
(C
78
C1
46
4.1
(1
(Section 4.5). Puriﬁed by column chromatography (4:1 CHCl3/
eOH) to yield 98 mg (99%) of 10 as a white amorphous product.
]D +33 (c 0.54, CH3OH); Rf: 0.34 (4:1 CHCl3/MeOH); 1H NMR
2O, 360 MHz) d (ppm) 7.82 (1H, s, CH@N), 7.72–7.68 (5H, m,
), 4.97 (1H, d, J1,2 = 8.3 Hz, H-1), 3.90 (1H, dd, J5,6b = 1.5 Hz,
,6b = 11.7 Hz, H-6b), 3.75 (1H, dd, J5,6a = 5.2 Hz, H-6a), 3.62–3.48
H, m, H-2, H-3, H-4, H-5). 13C NMR (D2O+1 drop CH3OH,
0 MHz) d (ppm) 158.4 (NHCONH), 144.1 (CH@N), 135.7, 130.9,
9.7, 128.1 (Ar), 82.4, 79.4, 78.8, 73.9, 71.4 (C-1 to C-5), 62.7 (C-
. Anal. Calcd for C14H19N3O6 (325.32): C, 51.69; H, 5.89; N,
.92. Found: C, 51.57; H, 5.99; N, 12.81.
5. 4-Methylbenzaldehyde 4-(b-D-
copyranosyl)semicarbazone (11)
From 4 (0.09 g, 0.18 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (4:1 CHCl3/
eOH) to yield 60 mg (98%) of 11 as a white amorphous product.
] +30 (c 0.48, CH OH); R : 0.48 (3:1 CHCl /MeOH); 1H NMRD 3 f 3
D OD, 360 MHz) d (ppm) 7.85 (1H, s, CH@N), 7.59 (2H, d, M
510[a
(C
Ar
J6a
(4
15
79
C1
H,
4.2
520(1
(S
M
[a
(C
(1
H-
3,
143
8.5 Hz, Ar), 7.20 (2H, d, J = 8.5 Hz, Ar), 4.97 (1H, d, J1,2 = 8.4 Hz,
1), 3.89 (1H, dd, J5,6b < 1.0 Hz, J6a,6b = 11.7 Hz, H-6b), 3.73 (1H,
, J5,6a = 3.8 Hz, H-6a), 3.48–3.35 (4H, m, H-2, H-3, H-4, H-5),
5 (3H, s, CH3). 13C NMR (CD3OD, 360 MHz) d (ppm) 158.4
HCONH), 144.1 (CH@N), 141.3, 133.0, 130.4, 128.1 (Ar), 82.4,
.5, 78.9, 74.0, 71.4 (C-1 to C-5), 62.7 (C-6), 21.5 (CH3). Anal. Calcd
r C15H21N3O6 (339.34): C, 53.09; H, 6.24; N, 12.38. Found: C,
.98; H, 6.35; N, 12.26.
6. 4-Nitrobenzaldehyde 4-(b-D-glucopyranosyl)
micarbazone (12)
From 5 (0.15 g, 0.28 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (1:1 CHCl3/
eOH) to yield 107 mg (93%) of 12 as an orange amorphous prod-
t. [a]D +30 (c 0.29, DMSO); Rf: 0.70 (2:3 CHCl3/MeOH); 1H NMR
D3OD, 400 MHz) d (ppm) 8.28 (2H, d, J = 8.7 Hz, Ar), 8.00 (2H,
J = 9.0 Hz, Ar), 7.98 (1H, s, CH@N), 4.94 (1H, d, J1,2 = 8.5 Hz, H-
, 3.84 (1H, dd, J5,6b = 1.0 Hz, J6a,6b = 12.3 Hz, H-6b), 3.70 (1H, dd,
6a = 4.5 Hz, J6a,6b = 11.9 Hz, H-6a), 3.51–3.43 (2H, m, H-2 or H-3
H-4, H-5), 3.40–3.36 (2H, m, H-2 and/or H-3, and/or H-4). 13C
R (DMSO-d6, 360 MHz) d (ppm) 155.0 (NHCONH), 147.3 (C–
2), 138.0 (CH@N), 141.0, 127.8, 129.8 (Ar), 80.9, 78.4, 77.4,
.9, 69.9 (C-1 to C-5), 61.0 (C-6). Anal. Calcd for C14H18N4O8
C-
5.6
ease cite this article in press as: Tóth, M.; et al. Carbohydr. Res. (2013),70.31): C, 45.41; H, 4.90; N, 15.13. Found: C, 45.54; H, 4.79; N,
.24.
7. 4-Fluorobenzaldehyde 4-(b-D-glucopyranosyl)
micarbazone (13)
From 6 (0.12 g, 0.24 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (4:1 CHCl3/
eOH) to yield 80 mg (98%) of 13 as a brown amorphous product.
]D +42 (c 0.28, DMSO); Rf: 0.20 (4:1 CHCl3/MeOH); 1H NMR
D3OD, 400 MHz) d (ppm) 7.89 (1H, s, CH@N), 7.78 (2H, dd,
5.6 Hz, J = 8.5 Hz, Ar), 7.15 (2H, pt, J = 8.7 Hz, Ar), 4.95 (1H, d,
2 = 8.4 Hz, H-1), 3.86 (1H, dd, J5,6b < 1.0 Hz, J6a,6b = 11.7 Hz, H-
), 3.70 (1H, dd, J5,6a = 4.0 Hz, H-6a), 3.48–3.29 (4H, m, H-2, H-3,
4, H-5). 13C NMR (DMSO-d6, 360 MHz) d (ppm) 162.8 (d,
246.4 Hz, Ar), 155.4 (NHCOHN), 138.0 (CH@N), 131.2, 129.2 (d,
6.4 Hz, Ar), 115.8 (d, J = 21.6 Hz, Ar), 80.9, 78.4, 77.5, 72.1, 70.1
-1 to C-5), 61.1 (C-6). Anal. Calcd for C14H18FN3O6 (343.31): C,
.98; H, 5.28; N, 12.24. Found: C, 49.10; H, 5.41; N, 12.13.
8. 3-Chlorobenzaldehyde 4-(b-D-glucopyranosyl)
micarbazone (14)
From 7 (0.15 g, 0.28 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (4:1 CHCl3/
eOH) to yield 96 mg (94%) of 14 as a yellow amorphous product.
]D +30 (c 0.54, CH3OH); Rf: 0.40 (4:1 CHCl3/MeOH); 1H NMR
D3OD, 360 MHz) d (ppm) 7.83–7.32 (5H, m, Ar, CH@N), 4.97
H, d, J1,2 = 8.3 Hz, H-1), 3.85 (1H, dd, J5,6b < 1.0 Hz, J6a,6b = 11.8 Hz,
6b), 3.71–3.67 (1H, m, H-6a), 3.52–3.39 (4H, m, H-2, H-3, H-4, H-
. 13C NMR (CD3OD, 360 MHz) d (ppm) 158.2 (NHCONH), 142.4
H@N), 137.8, 135.8, 131.2, 130.6, 127.3, 126.9 (Ar), 82.4, 79.4,
.8, 73.8, 71.3 (C-1 to C-5), 62.6 (C-6). Anal. Calcd for
4H18ClN3O6 (359.76): C, 46.74; H, 5.04; N, 11.68. Found: C,
.62; H, 5.13; N, 11.80.
9. 1-Naphthaldehyde 4-(b-D-glucopyranosyl)semicarbazone
5)
From 8 (0.17 g, 0.18 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (4:1 CHCl3/
eOH) to yield 93 mg (80%) of 15 as a brown amorphous product.
]D +32 (c 0.48, CH3OH); Rf: 0.41 (4:1 CHCl3/MeOH); 1H NMR
D3OD, 360 MHz) d (ppm) 8.66 (1H, s, CH@N), 8.41–7.48 (7H, m,
), 4.98 (1H, d, J1,2 = 8.7 Hz, H-1), 3.87 (1H, dd, J5,6b = 1.5 Hz,
,6b = 12.0 Hz, H-6b), 3.71 (1H, dd, J5,6a = 4.6 Hz, H-6a), 3.52–3.38
H, m, H-2, H-3, H-4, H-5). 13C NMR (CD3OD, 360 MHz) d (ppm)
8.3 (NHCONH), 142.3 (CH@N), 135.3–124.1 (Ar), 82.4, 79.5,
.0, 74.1, 71.4 (C-1 to C-5), 62.7 (C-6). Anal. Calcd for
8H21N3O6 (375.38): C, 57.59; H, 5.64; N, 11.19. Found: C, 57.70;
5.52; N, 11.29.
0. 2-Naphthaldehyde 4-(b-D-glucopyranosyl)semicarbazone
6)
From 9 (0.14 g, 0.26 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (4:1 CHCl3/
eOH) to yield 96 mg (98%) of 16 as a white amorphous product.
]D +39 (c 0.47, CH3OH); Rf: 0.43 (4:1 CHCl3/MeOH); 1H NMR
D3OD, 360 MHz) d (ppm) 8.08–7.46 (8H, m, Ar, CH@N), 4.97
H, d, J1,2 = 8.6 Hz, H-1), 3.87 (1H, dd, J5,6b < 1.0 Hz, J6a,6b = 12.0 Hz,
6b), 3.71 (1H, dd, J5,6a = 4.3 Hz, H-6a), 3.51–3.38 (4H, m, H-2, H-
H-4, H-5). 13C NMR (CD3OD, 360 MHz) d (ppm) 157.9 (NHCONH),
3.9 (CH@N), 135.6–123.9 (Ar), 82.4, 79.5, 78.9, 74.0, 71.4 (C-1 to5305), 62.7 (C-6). Anal. Calcd for C18H21N3O6 (375.38): C, 57.59; H,
4; N, 11.19. Found: C, 57.46; H, 5.75; N, 11.08.
http://dx.doi.org/10.1016/j.carres.2013.04.025
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2 May 20134.21. 5-Phenyl-2-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosylamino)-1,3,4-oxadiazole (17)
(a) From 3 (0.11 g, 0.23 mmol) according to General procedure
(Section 4.3). Puriﬁed by column chromatography (1:1 EtOAc/hex
ane) to yield 50 mg (45%) of 17 as a white amorphous product.
(b) From 3 (0.25 g, 0.51 mmol) according to General procedur
III (Section 4.4). Puriﬁed by column chromatography (1:1 EtOAc
hexane) to yield 212 mg (85%) of 17 as a white amorphous produc
[a]D –20 (c 0.28, CHCl3); Rf: 0.23 (1:1 EtOAc/hexane);1H NM
(CDCl3, 360 MHz) d (ppm) 7.96–7.83 (2H, m, Ar), 7.54–7.42 (3H
m, Ar), 6.22 (1H, br s, NH), 5.39 (1H, pt, J = 9.4 Hz, H-2 or H-3 o
H-4), 5.21 (1H, d, J1,2 = 9.0 Hz, H-1), 5.14, 5.11 (2H, 2 pt, J = 9.4
9.9 Hz in each, H-2 and/or H-3, and/or H-4), 4.33 (1H, dd
J5,6a = 4.5 Hz, J6a,6b = 12.5 Hz, H-6a), 4.11 (1H, dd, J5,6b = 1.2 Hz, H
6b), 3.98–3.88 (1H, m, H-5), 2.09, 2.06, 2.05 (12H, 3 s, CH3). 13
NMR (CDCl3, 360 MHz) d (ppm) 170.8, 170.5, 169.8, 169.5 (CO
161.4, 160.0 (C-oxadiazole), 131.0, 128.9, 125.0, 123.8 (Ar), 82.7
73.4, 72.6, 70.6, 68.1 (C-1 to C-5), 61.6 (C-6), 20.6, 20.5 (CH3). Ana
Calcd for C22H25N3O10 (491.45): C, 53.77; H, 5.13; N, 8.55. Found: C
53.89; H, 5.24; N, 8.64.
4.22. 5-(4-Methylphenyl)-2-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosylamino)-1,3,4-oxadiazole (18)
From 4 (0.29 g, 0.57 mmol) according to General procedure I
(Section 4.4). Puriﬁed by column chromatography (1:1 EtOAc/hex
ane) to yield 190 mg (66%) of 18 as awhite amorphous product. [a]
–14 (c 0.27, CHCl3); Rf: 0.31 (1:1 EtOAc/hexane);1H NMR (CDCl
360 MHz) d (ppm) 7.78 (2H, d, J = 8.1 Hz, Ar), 7.24 (2H, d
J = 8.0 Hz, Ar), 6.40 (1H, br s, NH), 5.38 (1H, pt, J = 9.4 Hz, H-2 o
H-3 or H-4), 5.21 (1H, d, J1,2 = 9.3 Hz, H-1), 5.14, 5.12 (2H, 2 p
J = 9.3, 9.7 Hz in each, H-2 and/or H-3, and/or H-4), 4.31 (1H, dd
J6a,6b = 12.5 Hz, H-6a), 4.09 (1H, dd, H-6b), 3.92 (1H, ddd
J5,6a = 4.2 Hz, J5,6b = 1.8 Hz, J4,5 = 9.8 Hz, H-5), 2.39, 2.07, 2.04, 2.0
(16H, 4 s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 170.6, 170.5
169.8, 169.4 (CO), 161.2, 160.0 (C-oxadiazole), 141.3, 129.5, 125.9
121.0 (Ar), 82.6, 73.2, 72.7, 70.5, 68.0 (C-1 to C-5), 61.6 (C-6), 21.
(CH3), 20.6, 20.5 (CH3). Anal. Calcd for C23H27N3O10 (505.47): C
54.65; H, 5.38; N, 8.31. Found: C, 54.78; H, 5.49; N, 8.42.
4.23. 5-(4-Nitrophenyl)-2-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosylamino)-1,3,4-oxadiazole (19)
(a) From 5 (0.19 g, 0.35 mmol) according to General proce
dure II (Section 4.3). Puriﬁed by column chromatography (1:
EtOAc/hexane) to yield 80 mg (43%) of 19 as a white amorphou
product.
(b) From 5 (0.25 g, 0.46 mmol) according to General procedur
III (Section 4.4). Puriﬁed by column chromatography (1:1 EtOAc
hexane) to yield 130 mg (53%) of 19 as a white amorphous produc
[a]D –21 (c 0.23, CHCl3); Rf: 0.27 (1:1 EtOAc/hexane);1H NM
(CDCl3, 360 MHz) d (ppm) 8.34 (2H, d, J = 8.6 Hz, Ar), 8.10 (2H, d
J = 8.6 Hz, Ar), 6.45 (1H, br s, NH), 5.41 (1H, pt, J = 9.4 Hz, H-2 o
H-3 or H-4), 5.24 (1H, d, J1,2 = 9.0 Hz, H-1), 5.16, 5.12 (2H, 2 p
J = 9.7, 10.0 Hz in each, H-2 and/or H-3, and/or H-4), 4.34 (1H
dd, J5,6a = 4.3 Hz, J6a,6b = 12.5 Hz, H-6a), 4.14 (1H, dd, J5,6b < 1.0 H
H-6b), 4.00–3.91 (1H, m, H-5), 2.10, 2.07 (12H, 2 s, CH3). 13
NMR (CDCl3, 360 MHz) d (ppm) 170.9, 170.5, 169.8, 169.5 (CO
162.1, 158.2 (C-oxadiazole), 148.9 (C–NO2), 129.3, 126.7, 124.
(Ar), 82.6, 73.4, 72.5, 70.6, 68.0 (C-1 to C-5), 61.5 (C-6), 20.6, 20.
(CH3). Anal. Calcd for C22H24N4O12 (536.45): C, 49.26; H, 4.51; N
10.44. Found: C, 49.37; H, 4.42; N, 10.33.Please cite this article in press as: Tóth, M.; et al. Carbohydr. Res. (204.24. 5-(4-Fluorophenyl)-2-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosylamino)-1,3,4-oxadiazole (20)
(a) From 6 (0.20 g, 0.39 mmol) according to General procedure
(4.3). Puriﬁed by column chromatography (1:1 EtOAc/hexane) t
yield 48 mg (24%) of 20 as a white amorphous product.
(b) From 6 (0.1 g, 0.19 mmol) according to General procedure I
(4.4). Puriﬁed by column chromatography (1:1 EtOAc/hexane) t
yield 85 mg (88%) of 20 as a white amorphous product. [a]D= –
(c 0.30, CHCl3); Rf: 0.33 (1:1 EtOAc/hexane); 1H NMR (CDCl
360 MHz) d (ppm) 7.91 (2H, dd, J = 5.4 Hz, J = 8.2 Hz, Ar), 7.1
(2H, pt, J = 8.4 Hz Ar), 6.27 (1H, br s, NH), 5.39 (1H, pt, J = 9.4 H
H-2 or H-3 or H-4), 5.21 (1H, d, J1,2 = 9.2 Hz, H-1), 5.14, 5.10 (2H
2 pt, J = 9.3, 9.8 Hz in each, H-2 and/or H-3, and/or H-4), 4.3
(1H, dd, J5,6a = 4.3 Hz, J6a,6b = 12.3 Hz,H-6a), 4.12 (1H, dd
J5,6b < 1.0 Hz, H-6b), 3.98–3.88 (1H, m, H-5), 2.09, 2.06, 2.05 (12H
3s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 170.8, 170.5, 169.8
169.5 (CO), 164.1 (d, J = 252.0 Hz, Ar), 161.4, 159.1 (C-oxadiazole
128.2 (d, J = 8.0 Hz, Ar), 120.1, 116.2 (d, J = 22.3 Hz, Ar), 82.6, 73.3
72.6, 70.5, 68.0 (C-1 to C-5), 61.5 (C-6), 20.6, 20.5 (CH3). Anal. Calc
for C22H24FN3O10 (509.44): C, 51.87; H, 4.75; N, 8.25. Found: C
51.76; H, 4.87; N, 8.38.
4.25. 5-(3-Chlorophenyl)-2-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosylamino)-1,3,4-oxadiazole (21)
(a) From 7 (0.13 g, 0.24 mmol) according to General procedure
(Section 4.3). Puriﬁed by column chromatography (1:1 EtOAc/hex
ane) to yield 65 mg (52%) of 21 as a white amorphous product.
(b) From 7 (0.17 g, 0.33 mmol) according to General procedur
III (Section 4.4). Puriﬁed by column chromatography (1:1 EtOAc
hexane) to yield 110 mg (64%) of 21 as a white amorphous produc
[a]D –13 (c 0.32, CHCl3); Rf: 0.29 (1:1 EtOAc/hexane);1H NM
(CDCl3, 360 MHz) d (ppm) 7.89 (1H, br s, Ar), 7.80 (1H, d
J = 7.3 Hz, Ar), 7.51–7.36 (2H, m, Ar), 6.22 (1H, br s, NH), 5.3
(1H, pt, J = 9.4 Hz, H-2 or H-3 or H-4), 5.21 (1H, d, J1,2 = 9.2 Hz, H
1), 5.14, 5.10 (2H, 2 pt, J = 9.4, 9.8 Hz in each, H-2 and/or H-3
and/or H-4), 4.33 (1H, dd, J5,6a = 4.4 Hz, J6a,6b = 12.4 Hz, H-6a
4.13 (1H, dd, J5,6b < 1.0 Hz, H-6b), 3.99–3.90 (1H, m, H-5), 2.09
2.06, 2.05 (12H, 3 s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm
170.9, 170.5, 169.8, 169.5 (CO), 161.5, 158.8 (C-oxadiazole
135.0, 131.0, 130.3, 125.9, 125.4, 124.1 (Ar), 82.6, 73.4, 72.6, 70.6
68.1 (C-1 to C-5), 61.6 (C-6), 20.6, 20.5 (CH3). Anal. Calcd fo
C22H24ClN3O10 (525.89): C, 50.25; H, 4.60; N, 7.99. Found: C
50.38; H, 4.71; N, 7.89.
4.26. 5-(1-Naphthyl)-2-(2,3,4,6-tetra-O-acetyl-b-D-
glucopyranosylamino)-1,3,4-oxadiazole (22)
From 8 (0.34 g, 0.63 mmol) according to General procedure I
(Section 4.4). Puriﬁed by column chromatography (1:1 EtOAc/hex
ane) to yield 305 mg (89%) of 22 as a white amorphous produc
[a]D –10 (c 0.29, CHCl3); Rf: 0.32 (1:1 EtOAc/hexane); 1H NM
(CDCl3, 360 MHz) d (ppm) 9.01 (1H, d, J = 8.4 Hz, Ar), 7.86–7.6
(3H, m, Ar), 7.52–7.26 (3H, m, Ar), 6.94 (1H, br s, NH), 5.32 (1H
pt, J = 9.2 Hz, H-2 or H-3 or H-4), 5.19 (1H, d, J1,2 = 9.0 Hz, H-1
5.09, 5.06 (2H, 2 pt, J = 9.5, 9.8 Hz in each, H-2 and/or H-3, and/o
H-4), 4.22 (1H, dd, J5,6a = 4.0 Hz, J6a,6b = 12.7 Hz, H-6a), 4.02 (1H
dd, J5,6b < 1.0 Hz, H-6b), 3.90–3.80 (1H, m, H-5), 1.98, 1.93, 1.9
(12H, 3 s, CH3). 13C NMR (CDCl3, 360 MHz) d (ppm) 170.3, 170.2
169.7, 169.3 (CO), 161.2, 159.5 (C-oxadiazole), 133.4–120.1 (Ar
82.4, 73.1, 72.7, 70.4, 67.9 (C-1 to C-5), 61.5 (C-6), 20.3 (CH3). Ana
Calcd for C26H27N3O10 (541.51): C, 57.67; H, 5.03; N, 7.76. Found: C
57.55; H, 5.12; N, 7.63.13), http://dx.doi.org/10.1016/j.carres.2013.04.025
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Pl7. 5-(2-Naphthyl)-2-(2,3,4,6-tetra-O-acetyl-b-D-
copyranosylamino)-1,3,4-oxadiazole (23)
From 9 (0.31 g, 0.57 mmol) according to General procedure II
ection 4.3). Puriﬁed by column chromatography (1:1 EtOAc/hex-
e) to yield 150 mg (49%) of 23 as a white amorphous product.
]D 19 (c 0.28, CHCl3); Rf: 0.20 (1:1 EtOAc/hexane); 1H NMR
DCl3, 400 MHz) d (ppm) 8.34 (1H, s, Ar), 8.10–7.69 (4H, m, Ar),
8–7.40 (2H, m, Ar), 6.09 (1H, br s, NH), 5.41 (1H, pt, J = 9.4 Hz,
2 or H-3 or H-4), 5.25 (1H, d, J1,2 = 8.3 Hz, H-1), 5.15, 5.12 (2H,
pt, J = 9.2, 9.8 Hz in each, H-2 and/or H-3, and/or H-4), 4.35
H, dd, J5,6a = 3.8 Hz, J6a,6b = 12.2 Hz, H-6a), 4.13 (1H, dd,
6b < 1.0 Hz, H-6b), 4.02–3.88 (1H, m, H-5), 2.10, 2.06 (12H, 2 s,
3). 13C NMR (CDCl3, 360 MHz) d (ppm) 171.0, 170.6, 169.9,
9.5 (CO), 161.4, 160.2 (C-oxadiazole), 134.3–121.1 (Ar), 82.7,
.4, 72.6, 70.6, 68.1 (C-1 to C-5), 61.6 (C-6), 20.7, 20.5 (CH3). Anal.
lcd for C26H27N3O10 (541.51): C, 57.67; H, 5.03; N, 7.76. Found: C,
.79; H, 5.14; N, 7.87.
8. 2-(b-D-Glucopyranosylamino)-5-phenyl-1,3,4-oxadiazole
4)
From 17 (0.09 g, 0.18 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (4:1 CHCl3/
eOH) to yield 41 mg (70%) of 24 as a white amorphous product.
]D +7 (c 0.5, MeOH); Rf: 0.50 (3:1 CHCl3/MeOH); 1H NMR (CD3OD,
0 MHz) d (ppm) 7.94–7.84 (2H, m, Ar), 7.55–7.45 (3H, m, Ar),
0 (1H, d, J1,2 = 8.6 Hz, H-1), 3.87 (1H, dd, J5,6b = 1.3 Hz,
,6b = 11.8 Hz, H-6a), 3.68 (1H, dd, J5,6a = 5.0 Hz, H-6b), 3.50–3.33
H, m, H-2, H-3, H-4, H-5). 13C NMR (CD3OD, 360 MHz) d (ppm)
4.8, 160.7 (C-oxadiazole), 132.3, 130.3, 126.9, 125.1 (Ar), 85.6,
.5, 78.9, 74.2, 71.4 (C-1 to C-5), 62.7 (C-6). Anal. Calcd for
4H17N3O6 (323.30): C, 52.01; H, 5.30; N, 13.00. Found: C, 52.13;
5.19; N, 13.12.9. 2-(b-D-Glucopyranosylamino)-5-(4-methylphenyl)-1,3,4-
adiazole (25)
From 18 (0.14 g, 0.28 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (3:1 CHCl3/
eOH) to yield 31 mg (33%) of 25 as a white amorphous product.
]D +2 (c 0.18, DMSO); Rf: 0.40 (3:1 CHCl3/MeOH); 1H NMR
D3OD, 400 MHz) d (ppm) 7.80 (2H, d, J = 8.2 Hz, Ar), 7.34 (2H,
J = 8.0 Hz, Ar), 4.80 (1H, d, J1,2 = 8.7 Hz, H-1), 3.87 (1H, dd,
6b = 1.8 Hz, J6a,6b = 12.0 Hz, H-6b), 3.70 (1H, dd, J5,6a = 5.1 Hz, H-
), 3.50–3.35 (4H, m, H-2, H-3, H-4, H-5), 2.42 (3H, s, CH3). 13C
R (DMSO-d6, 360 MHz) d (ppm) 162.8, 157.9 (C-oxadiazole),
0.5, 129.7, 125.1, 121.3 (Ar), 84.4, 78.4, 77.4, 72.4, 69.8 (C-1 to
5), 60.8 (C-6), 21.0 (CH3). Anal. Calcd for C15H19N3O6 (337.33):
53.41; H, 5.68; N, 12.46. Found: C, 53.53; H, 5.59; N, 12.58.
0. 2-(b-D-Glucopyranosylamino)-5-(4-nitrophenyl)-1,3,4-
adiazole (26)
From 19 (0.13 g, 0.24 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (4:1 CHCl3/
eOH) to yield 70 mg (79%) of 26 as an orange amorphous prod-
t. [a]D +6 (c 0.15, DMSO); Rf: 0.19 (4:1 CHCl3/MeOH); 1H NMR
D3OD, 400 MHz) d (ppm) 8.40 (2H, d, J = 8.4 Hz, Ar), 8.16 (2H,
J = 8.4 Hz, Ar), 4.84 (1H, d, J1,2 = 8.7 Hz, H-1), 3.88 (1H, dd,
6b = 1.0 Hz, J6a,6b = 11.7 Hz, H-6b), 3.73–3.35 (5H, m, H-2, H-3,
4, H-5, H-6a). 13C NMR (DMSO-d6 + D2O, 360 MHz) d (ppm)
4.0, 157.2 (C-oxadiazole), 129.7, 126.8, 124.9 (Ar), 84.4, 78.6,
.3, 72.5, 70.0 (C-1 to C-5), 61.0 (C-6). Anal. Calcd for
4H16N4O8 (368.10): C, 45.66; H, 4.38; N, 15.21. Found: C, 45.77;
4.49; N, 15.12.
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adiazole (27)
From 20 (0.09 g, 0.18 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (4:1 CHCl3/
eOH) to yield 50 mg (83%) of 27 as a white amorphous product.
]D +4 (c 0.20, DMSO); Rf: 0.20 (4:1 CHCl3/MeOH); 1H NMR
D3OD, 400 MHz) d (ppm) 7.97 (2H, dd, J = 5.3 Hz, J = 8.6 Hz, Ar),
8 (2H, pt, J = 8.7 Hz, Ar), 4.80 (1H, d, J1,2 = 8.7 Hz, H-1), 3.88
H, dd, J5,6b = 1.6 Hz, J6a,6b = 12.0 Hz, H-6b), 3.70 (1H, dd,
6a = 5.2 Hz, H-6a), 3.50–3.30 (4H, m, H-2, H-3, H-4, H-5). 13C
R (DMSO-d6 + D2O, 360 MHz) d (ppm) 163.3 (d, J = 249.0 Hz,
), 163.0, 157.3 (C-oxadiazole), 128.0 (d, J = 7.2 Hz, Ar), 120.7
r), 116.6 (d, J = 22.4 Hz, Ar), 84.3, 78.4, 77.3, 72.4, 69.8 (C-1 to
5), 60.8 (C-6). Anal. Calcd for C14H16FN3O6 (341.29): C, 49.27;
4.27; N, 12.31. Found: C, 49.15; H, 4.38; 12.42.
2. 5-(3-Chlorophenyl)-2-(b-D-glucopyranosylamino)-1,3,4-
adiazole (28)
From 21 (0.11 g, 0.21 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (4:1 CHCl3/
eOH) to yield 55 mg (74%) of 28 as a white amorphous product.
]D +15 (c 0.21, DMSO); Rf: 0.19 (4:1 CHCl3/MeOH); 1H NMR
D3OD, 400 MHz) d (ppm) 7.90 (1H, br s, Ar), 7.84 (1H, d,
7.9 Hz, Ar), 7.56–7.48 (2H, m, Ar), 4.82 (1H, d, J1,2 = 8.7 Hz, H-
, 3.88 (1H, dd, J5,6b = 1.4 Hz, J6a,6b = 11.9 Hz, H-6b), 3.70 (1H, dd,
6a = 5.1 Hz, J6a,6b = 12.0 Hz, H-6a), 3.52–3.35 (4H, m, H-2, H-3,
4, H-5).13C NMR (DMSO-d6 + D2O, 360 MHz) d (ppm) 163.6,
7.5 (C-oxadiazole), 134.4, 131.8, 131.1, 126.0, 125.2, 124.4 (Ar),
.5, 78.6, 77.4, 72.7, 70.1 (C-1 to C-5), 61.2 (C-6). Anal. Calcd for
4H16ClN3O6 (357.75): C, 47.00; H, 4.51; N, 11.75. Found: C,
.10, H, 4.62; Cl, 9.93; N, 11.87.
3. 2-(b-D-Glucopyranosylamino)-5-(1-naphthyl)-1,3,4-
adiazole (29)
740From 22 (0.09 g, 0.24 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (3:1 CHCl3/
eOH) to yield 50 mg (84%) of 29 as a brown amorphous product.
]D +5 (c 0.18, DMSO); Rf: 0.40 (3:1 CHCl3/MeOH); 1H NMR
D3OD, 360 MHz) d (ppm) 9.00 (1H, d, J = 8.3 Hz, Ar), 8.06–7.88
H, m, Ar), 7.67–7.47 (3H, m, Ar), 4.90 (1H, d, J1,2 = 8.5 Hz, H-1),
3 (1H, dd, J5,6b = 2.0 Hz, J6a,6b = 12.0 Hz, H-6b), 3.93 (1H, dd,
6a = 5.3 Hz, H-6a), 3.66–3.40 (4H, m, H-2, H-3, H-4, H-5).13C
R (CD3OD, 360 MHz) d (ppm) 164.6, 160.5 (C oxadiazol),
5.3–121.7 (Ar), 85.7, 79.6, 74.2, 71.4 (C-1 to C-5), 62.7 (C-6).
750al. Calcd for C18H19N3O6 (373.36): C, 57.90; H, 5.13; N, 11.25.
und: C, 57.78; H, 5.24; N, 11.36.
4. 2-(b-D-Glucopyranosylamino)-5-(2-naphthyl)-1,3,4-
adiazole (30)
From 23 (0.12 g, 0.22 mmol) according to General procedure IV
ection 4.5). Puriﬁed by column chromatography (5:1 CHCl3/
eOH) to yield 70 mg (84%) of 30 as a white amorphous product.
]D +9 (c 0.20, DMSO); Rf: 0.20 (5:1 CHCl3/MeOH); 1H NMR
MSO-d6 + D2O, 360 MHz) d (ppm) 9.03 (1H, d, J = 8.4 Hz, Ar),
0 (1H, d, J = 8.2 Hz, Ar), 8.03 (2H, t, J = 7.3 Hz, Ar), 7.74–7.57
760H, m, Ar), 4.71 (1H, d, J1,2 = 8.1 Hz, H-1), 3.78–3.65 (1H, m, H-
), 3.45 (1H, dd, J5,6a = 5.6 Hz, J6a,6b = 11.7 Hz, H-6a), 3.32–3.20
H, m, H-2, H-3, H-4), 3.17–3.10 (1H, m, H-5). 13C NMR (DMSO-
+ D2O, 360 MHz) d (ppm) 162.7, 157.7 (C-oxadiazole), 133.4–
0.3 (Ar), 84.4, 78.5, 77.4, 72.5, 69.9 (C-1 to C-5), 61.2 (C-6). Anal.
lcd for C18H19N3O6 (373.36): C, 57.90; H, 5.13; N, 11.25. Found:
57.79; H, 5.22; N, 11.14.
http://dx.doi.org/10.1016/j.carres.2013.04.025
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